info@morphocell.com

+1 (514) 345 4931 ext. 7879

c/o CHU Sainte-Justine Research Center
3175 Ch. Côte-Sainte-Catherine
Montreal, QC, H3T 1C5

© Copyright Morphocell Technologies Inc 2019

  • i_mail
ReLiver

‚Äč

 

Derived from an unlimited stem cell source, our cell therapy platform will ultimately transform the treatment of liver disease. We are initially targeting acute and acute-on-chronic liver failure, the most challenging conditions that currently rely on liver transplantation as the only line of treatment.

®

ReLiver™ has been designed to be:

  • Used as an allogeneic cell therapy

  • Implantable via minimally invasive surgery

  • Fully functional upon implantation

  • Easily removed without sequelae once the patient’s liver regenerates

  • Does not require immunosuppression

  • Can be cryopreserved for on-demand use

Pre-clinical data supports that ReLiver® :

  • Maintains metabolic function for 12 weeks

  • Restores liver function in models of acute liver failure, improving survival and treating hepatic encephalopathy

  • Is safe: cells are contained within the implant

  • Effectively evades the host immune system